We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DABUR:NSEDabur India Limited Analysis

Data as of 2026-06-06 - not real-time

₹424.15

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Dabur India is trading at INR 424.15, below its 20‑day SMA of 447.30 and 50‑day SMA of 442.91, but still well above the 200‑day SMA of 491.49, indicating a short‑term pull‑back within a longer‑term downtrend. The RSI of 35.9 suggests the stock is approaching oversold territory, while the MACD line remains bearish with a widening histogram, pointing to lingering downside momentum. Support sits near INR 414.6 and resistance at INR 485, framing the current price action in a tight range. Recent Q4 FY26 results showed a 15% jump in net profit and a 7.3% revenue rise YoY, reinforcing the company's steady growth narrative, and a dividend of 8.25 ₹ per share (≈1.95% yield) was declared, supporting income‑focused investors. However, the DCF‑derived fair value of INR 191.36 versus the market price implies a substantial valuation gap, reflected in a high trailing PE of 39.8×. With a low beta of 0.38, increasing volume, and a “Extreme Greed” sentiment index, the stock presents a nuanced risk‑reward profile.
Given the overvaluation, modest upside of ~24% from analyst targets, strong cash balance, low debt‑to‑equity, and a sustainable dividend payout, Dabur remains attractive for long‑term holders seeking brand stability, but short‑term traders should respect the bearish technical cues and the proximity to key support levels.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near immediate support at INR 414.6
  • Bearish MACD momentum despite oversold RSI
  • Increasing volume indicating potential accumulation

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Consistent revenue and profit growth in FY26
  • Strong cash position and manageable debt
  • Attractive dividend yield with sustainable payout

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Robust brand moat in consumer defensive sector
  • Significant valuation premium over DCF fair value
  • Low beta and defensive positioning reduce market volatility

Key Metrics & Analysis

Financial Health

Revenue Growth7.30%
Profit Margin14.36%
P/E Ratio39.8
ROE16.24%
ROA7.35%
Debt/Equity10.91
P/B Ratio6.6
Op. Cash Flow₹25.8B
Free Cash Flow₹16.7B

Technical Analysis

TrendNeutral
RSI35.9
Support₹414.60
Resistance₹485.00
MA 20₹447.30
MA 50₹442.91
MA 200₹491.49
MACDBearish
VolumeIncreasing
Fear & Greed Index83.02

Valuation

Fair Value₹191.36
Target Price₹527.11
Upside/Downside24.27%
GradeOvervalued
TypeGrowth
Dividend Yield1.95%

Risk Assessment

Beta0.38
Volatility27.50%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.